CA
NZ
UK
AU
IND
US
Vertex Pharmaceuticals (NASDAQ:VRTX) built a remarkableBusinessby dominating the treatment of a single rare disease, cystic fibrosis. Now the crucial question forNasdaq100 investors is whether it can repeat that success elsewhere, because itsLong-term Growthdepends on expanding beyond theFranchisethat made it, into new areas such as …
Alnylam Pharmaceuticals (NASDAQ:ALNY) pioneered an entirely new class of medicine, drugs that silence disease-causing genes, and it is now turning that science into fast-growing commercial products. As those medicines reach more patients, Alnylam brings the promise of RNA-based therapies into theNasdaq100 growth debate, offering …
Amgen's (NASDAQ:AMGN) next chapter will be written by its pipeline, and one experimental medicine in particular has captured investors' attention: a monthly obesity injection that could let the company compete in one of the fastest-growing markets in healthcare. ForNasdaq100 investors, Amgen is a reminder …
● CalciMedica completed a one-for-fiveReverse Stock Spliteffective 31 August 2026 while reporting FDA alignment on a Phase 2b Auxora trial design and a roughly $49 million private placement.
● Cadrenal Therapeutics reported about $2.3 million in cash at 31 March 2026 and lined up an up-to-$8.8 million privatePlacementto extend its runway toward 2027.
● RVTY shares closed up 9.11% at $140.19, a fresh 52-week high, lifting marketCapitalizationto roughly $15.6 billion.
● The pullback followed a powerful run to record highs rather than any fresh negative development.
Healthcare inside theNasdaqComposite in September 2026 is not one story but several running at once. At the top of the barbell sit companies already turning products into profits. At the other end sit earlier-stage names still spending to prove a market exists. Tarsus Pharmaceuticals …
● GeneDx grew exome and genomeVolume32% year over year to 30,785 results in the second quarter of 2026, reached adjustedNet Incomeof $0.4 million, and reiterated full-yearRevenueguidance of $475 million to $490 million.
● Nakamoto, formerly KindlyMD, ended its healthcare clinic operations on June 19, 2026 and now operates as aBitcointreasury holding roughly 4,467 Bitcoin valued at about $261.5 million as of the second quarter of 2026.
Please wait processing your request...